The Relationship of Patient Age to the Pathobiology of the Clonal Myeloid Diseases

Seminars in Oncology

Volumn 31, Issue 2, 2004, Pages 185-197

  Lichtman, Marshall A ^a   Rowe, Jacob M ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CYTOPENIA; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MYELOID LEUKEMIA; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW;

EID: 1842862749     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.029     Document Type: Article

References (95)

1. Vardiman JW, Harris NL, Bruning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002
2. Pui C-H, Raimondi SC, Srivastava DK, et al: Prognostic factors in infants with acute myeloid leukemia. Leukemia 14:684-687, 2000
3. Webb DKH, Harrison G, Stevens RF, et al: Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 98:1714-1720, 2000
4. Wells RJ, Arthur DC, Srivasta A, et al: Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-607, 2002
5. Aricò M, Biondi A, Pui C-H: Juvenile myelomonocytic leukemia. Blood 90:479-488, 1997
6. McNally RJQ, Rowland D, Roman E, et al: Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 15:173-189, 1997
7. Vickers M, Jackson G, Taylor P: The incidence of acute promyelocytic leukemia appears constant over most of a human life span, implying only one rate-limiting mutation. Leukemia 14:722-726, 2000
8. Rowley J, Alimena G, Garson OM, et al: A collaborative study of the relationship of the morphological type of acute non lymphocytic leukemia with patient age and karyotype. Blood 59:1013-1022, 1982
9. Aul C, Gatterman N, Schneider W: Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82:358-367, 1992
10. Bauduer F, Ducout L, Dastugue N, et al: Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. Leuk Res 22:205-208, 1998
11. Christolini A, Mazzuccout MG, Ferrari A, et al: Essential thrombocythemia. Hematologica 75:537-540, 1990
12. Gruppo Italiano Studio Policitemia: Polycythemia vera: The natural history of 1,213 patients followed for 20 years. Ann Intern Med 123:656-664, 1995
13. Bloomfield CD, Shuma C, Regal L, et al: Long-term survival of patients with acute myeloid leukemia. A third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 80:2191-2198, 1997 (suppl S)
14. Grinwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
15. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96:4075-4083, 2000
16. Grinwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 98:1312-1320, 2001
17. Schoch C, Haferlach T, Haase D, et al: Patients with de novo acute myeloid leukemia and complex karyotypic aberrations show a poor prognosis despite intensive treatment, a study of 90 patients. Br J Haematol 112:118-126, 2001
18. Rossi C, Pelizzari AM, Bellotti D, et al: Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia 14:636-641, 2000
19. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
20. Schoch C, Kern W, Krawitz P, et al: Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood 98:3500, 2001 (letter)
21. Moorman AV, Roman E, et al: Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukemia. Br J Cancer 86:1061-1063, 2002
22. Neubauer A, Dodge RK, George SL, et al: Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 83:1603-1611, 1994
23. Coglan DW, Morley AA, Matthews JP, et al: The incidence and prognostic significance of mutations in codon 13 of the n-ras gene in acute myeloid leukemia. Leukemia 8:1682-1687, 1994
24. Wattel E, Preudhomme C, Hecquet B, et al: p53 gene mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-3157, 1994
25. Yokota S, Kiyoi H, Nakao M, et al: Internal tandem duplication of the FLT 3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: A study on a large series patients and cell lines. Leukemia 11:1605-1609, 1997
26. Kottaridis PD, Gale RE, Frew ME, et al: The presence of FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759, 2001
27. Abu-Duhier FM, Goodever AC, Willson JA, et al: FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 111:190-195, 2000
28. Rombouts WJ, Blokland I, Lowenberg B, et al: Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplication in the flt3 gene. Leukemia 14:675-683, 2000
29. Fröhling S, Schlenk RF, Beitruck J, et al: Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100:4372-4380, 2002
30. Stirewalt DL, Kopecky KJ, Meshinchi S, et al: FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97:3589-3595, 2001
31. Kiyoi H, Naoe T, Nakano Y, et al: Prognostic implications of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074-3080, 1999
32. Nørgaard JM, Langkjer ST., Palshof T, et al: Relation of blast cell survival to chemotherapy resistance in AML. Br J Haematol 93:888-897, 1996
33. Banker DE, Groudine M, Norwood T, et al: Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood 89:243-255, 1997
34. Garrido SM, Cooper JJ, Appelbaum FR, et al: Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. Leuk Res 25:23-32, 2001
35. Leith CP, Kopecky KJ, Godwin J, et al: Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 89:3323-3329, 1997
36. Leith CD, Kopecky KJ, Chen I-M, et al: Frequency and clinical significance of the expression of the multidrug resistance protein MDR1/P glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwestern Oncology Group study. Blood 94:1086-1099, 1999
37. Nørgaard JM, Olesen G, Kristensen JS, et al: Leukaemia cell drug resistance and prognostic factors in AML. Eur J Haematol 68:219-228, 1999
38. Fialkow PJ, Singer JW, Raskind WH, et al: Clonal development, stem cell differentiation, and clinical remission in acute non-lymphocytic leukemia. N Engl J Med 317:468-473, 1987
39. Turhan AG, Lemoine FM, Debert C, et al: Highly purified primitive hematopoietic cells are PML-RARα negative and generate non-clonal progenitors in acute promyelocytic leukemia. Blood 85:2154-2161, 1995
40. Vendetti A, Del Poeta G, Buccisano F, et al: Biologic features of acute myeloid leukemia in the elderly. Blood 92:697-699, 1998
41. Suárez L, Belén Vidriales M, García-Laraña J, et al: Multiparametric analysis of apoptotic and multidrug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia. Haematologica 86:1287-1295, 2001
42. Baudard M, Marie JP, Cadiou M, et al: Acute myelogenous leukaemia in the elderly: Retrospective study of 235 consecutive patients. Br J Haematol 86:82-91, 1994
43. Estey EH: How I treat older patients with AML. Blood 96:1670-1673, 2000
44. Johnson PRE, Liu Yin JA: Prognostic factors in elderly patients with acute myeloid leukaemia. Leuk Lymph 16:51-56, 1994
45. Stein RS, Wolff SN, Greer JP, et al: Age and cytogenetics as predictors of event free survival in patients with acute non-lymphoid leukemia receiving high dose cytosine arabinoside and daunorubicin as consolidation chemotherapy. Leuk Lymph 42:913-922, 2001
46. Menzin J, Lang K, Earle CC, et al: The outcome and costs of acute myeloid leukemia among the elderly. Arch Intern Med 162:1597-1603, 2002
47. Åström M, Bodin L, Nilsson I, et al: Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden. Br J Cancer 82:1387-1392, 2000
48. Rowe JM: Treatment of acute myelogenous leukemia in older patients. Leukemia 14:480-487, 2000
49. Latagliata R, Petti MC, Mandelli F: Acute myeloid leukemia in the elderly: "Peraspera ad astra"? Leuk Res 23:603-613, 1999
50. Pinto A, Zagonel V, Ferrara F: Acute myeloid leukemia in the elderly: Biology and therapeutic strategies. Crit Rev Oncol Hematol 39:275-287, 2001
51. Hiddeman W, Kern W, Schoch C, et al: Management of acute myeloid leukemia in elderly patients. J Clin Oncol 17:3569-3576, 1999
52. Baudard M, Beauchamp-Nicoud A, Delman A, et al: Has the prognosis for acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16 year period. Leukemia 13:1481-1490, 1999
53. Ellison RR, Holland JF, Weil M, et al: Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults. Blood 33:507-523, 1968
54. Yates JW, Wallace HJ, Ellison RR, et al: Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chem Rep 57:485-488, 1973
55. Feldman EJ, Seiter K, Damon L, et al: A randomized trial of high-vs standard-dose mitoxantrone in elderly patients with acute myeloid leukemia. Leukemia 71:485-499, 1997
56. Goodwin JE, Kopecky KJ, Head DR, et al: A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031). Blood 97:3607-3615, 1998
57. Leone F, Ciolli S, Giuliani A, et al: Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. Br J Haematol 90:169-174, 1995
58. Manoharan A, Trickett A, Kwan YL, et al: Flexible low intensity combination chemotherapy for elderly patients with acute myeloid leukemia. Int J Hematol 75:519-527, 2002
59. Hartmann F, Jacobs G, Gotto H, et al: Cytosine arabinoside, idarubicin, and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients. Leuk Lymphoma 42:347-355, 2001
60. Letendre L, Noel P, Litzow MR, et al: Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose Ara-C. Am J Clin Oncol 2:142-144, 1998
61. Leone G, Sica S, Pagano L: Idarubicin including regimens in acute myelogenous leukemia in elderly patients. Crit Rev Oncol Hematol 32:59-68, 1999
62. Heyll A, Aul C, Goglin F, et al: Results of conventional dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia. Ann Hematol 68:279-283, 1994
63. Jackson GH, Taylor PRA, Galloway MJ, et al: The use of oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukemia in the elderly: A report of toxicity and efficacy. Leukemia 11:1193-1196, 1997
64. Löwenberg B, Suciu S, Archimbaud E, et al: Mitoxantrone versus daunorubicin in induction consolidation chemotherapy - The value of low-dose cytarabine for maintenance of remission and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group randomized phase III study AML-9. J Clin Oncol 16:872-881, 1998
65. Goldstone AH, Burnett AK, Wheatley K, et al: Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The result of the United Kingdom Medical Research Council AML11 trial. Blood 98:1302-1311, 2001
66. Rowe JM, Neuberg D, Freidenberg W, et al: A phase III study of daunorubicin vs idarubicin vs mitoxantrone for older patients (>55) with acute myelogenous leukemia(AML): A study of the Eastern Cooperative Oncology Group (E3993). Blood 92:1284a, 1998 (suppl 1, abstr)
67. Wahlin A, Markevärn B, Golovleva I, et al: Prognostic significance of risk group stratification in elderly patients with acute myeloid leukemia. Br J Haematol 115:25-33, 2001
68. de Lima M, Ghjaddar H, Pierce S, et al: Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol 93:89-95, 1996
69. Ferrara F, Annunziata M, Capia C, et al: Therapeutic options for patients over 75 years of age with acute myeloid leukemia. Haematologica 83:126-131, 1998
70. Hernandez-Baluda JC, Sierra J, Esteve J, et al: Treatment of elderly patients with AML: Results of an individual approach. Haematologica 83:34-39, 1998
71. Stone RM, Berg DT, George SL, et al: Postremission therapy in older patients with de novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98:548-553, 2001
72. Montillo M, Tedeschi A, Pagano L, et al: Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia. A pilot study from the Gimema group. Br J Haematol 111:334-337, 2000
73. Schiller GJ: Postremission therapy of acute myeloid leukemia in older adults. Leukemia 10:518-520, 1996 (suppl 1)
74. Cahn JY, Labopin M, Mandelli F, et al: Autologous bone marrow transplantation for first remission of acute myeloblastic leukemia in patients older than 50 years: A retrospective analysis of the European Bone Marrow Transplant Group. Blood 85:575-579, 1995
75. Lyman GH, Balducci L, Agboola Y: Use of hematopoietic growth factors in older cancer patients. Oncol Spectrums 2:414-421, 2001
76. Bokemeyer C, Honecker F, Wedding U, et al: Use of hematopoietic growth factors in elderly [patients receiving cytotoxic chemotherapy. Onkologie 25:32-39, 2002
77. Rowe JM, Liesveld JL: Hematopoietic growth factors in acute leukemia. Leukemia 11:328, 1997
78. Bennett CL, Hynes D, Godwin J, et al: Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group Trial. Cancer Invest 19:603-610, 2001
79. Woronoff-Lemsi MC, Witz F, Arveux P, et al: Intérêt thérapeutique et économique du GM-CSF dans le traitment des leucémies aiguës myéloblasiques du sujet âgé: Protocole GOELAM Sa3. Therapie 56:131-133, 2001
80. Spataro V, Kovacsovics T, Bach S, et al: Acute myeloid leukemia in the elderly: Results of an individualized approach in two centres. Leuk Lymph 39:521-530, 2000
81. López A, de la Rubia J, Martín G, et al: Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. Leuk Res 25:685-692, 2001
82. Harousseau J-L: Acute myeloid leukemia in the elderly. Blood Rev 12:145-153, 1998
83. Yoshida S, Kuriyama K, Miyazaki Y, et al: De novo acute myeloid leukemia in the elderly: A consistent fraction of long-term survivors by standard-dose chemotherapy. Leuk Res 25:33-38, 2001
84. Wahlin A, Makervarn B, Golovleva I, et al: Improved outcome in adult acute myeloid leukemia in almost entirely restricted to young patients and associated with stem cell transplantation. Eur J Hematol 68:54-63, 2002
85. Wick G, Grubeck-Loehenstein B: The aging immune system: Primary and secondary alterations of immune reactivity in the elderly. Exp Gerontol 32:401-413, 1997
86. Latagliata R, Alimena G, Carmosino I, et al: Conservative treatment for patients over 80 years with acute myelogenous leukemia. Am J Hematol 71:256-259, 2002
87. Larson RA, Boogaerts M, Estey E, et al: Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 16:1627-1636, 2002
88. Chakraverty R, Peggs K, Chopra R, et al: Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen. Blood 99:1071-1078, 2002
89. Schlenk RF, Hartmann F, Hensel M, et al: Less intense conditioning with fludarabine, cyclophosphamide, idarubicin, and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia. Leukemia 126:581-586, 2002
90. Baer MR, George SL, Dodge RK, et al: Phase 3 study of the multidrug resistance modulator PSC-833 in primarily untreated patients over 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720. Blood 100:1224-1232, 2002
91. Rossi HA, O'Donnell J, Sarcinelli FM, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 16:310-315, 2002
92. Saito K, Nakamura Y, Aoyagi M, et al: Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 71:238-244, 2000
93. Lancet JE, Karp JE: Farnesyltransferase inhibitors in hematologic malignancies: New horizons in therapy. Blood 102:3880-3889, 2003
94. Smith BD, Levis M, Brown P, et al: Single agent CEP-701, a novel FLT-3 inhibitior, shows initial response in patients with refractory acute myeloid leukemia. Blood 100:85a, 2002
95. Marucci G, Stock W, Klisovic I, et al: In vivo activity of Genasense (G3139)(GS), a Bcl-2 antisense oligonucleotide in previously untreated patients >60 years with acute myeloid leukemia (AML): Initial report of a phase I study in combination with daunorubicin and cytarabine. Blood 100:337a, 2002 (abstr)